Regression of A549 lung cancer tumors by anti-miR-150 vector

YOU-JIE LI1*, YAN-XIA ZHANG1*, PING-YU WANG1, YONG-LIANG CHI2, CHAO ZHANG1, YING MA1, CHANG-JUN LV3 and SHU-YANG XIE1

1Institute of Medical Molecular Genetics, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yan Tai 264003; 2Shandong China Traditional Medical Affiliated Hospital, Ji Nan 250012; 3The Affiliated Hospital to Binzhou Medical University, Binzhou 256603, P.R. China

Received July 25, 2011; Accepted August 23, 2011

DOI: 10.3892/or.2011.1466

Abstract. microRNAs (miRNAs) have been shown to play a role in cancer. Antisense oligonucleotides can bind directly to miRNAs and block their activity, which are generally named anti-miRNAs. To suppress A549 cell proliferation in vitro and in vivo by anti-miRNAs, an anti-miR-150 expression vector (PR-ASO-150), regulated by the H1 promoter and containing a ‘TTTTT’ sequence following a hairpin to stop transcription, was constructed. A549 cell proliferation in vitro or in nude mice was observed after PR-ASO-150 treatment. Our results showed that miR-150 expression was inhibited and the growth inhibition rate of A549 cells was higher in the PR-ASO-150-treated group compared with the control, which indicated that PR-ASO-150 could inhibit A549 cell proliferation by regulating miR-150 expression. Following establishment of A549 cancer cell xenografts in nude mice, PR-ASO-150 was delivered intratumorally to investigate the suppressive action to tumor proliferation by regulating miR-150 expression. The results indicate that the tumor volume and weight were lower compared to the control group. Our results further showed that p53 expression was higher after tumor tissue was treated with PR-ASO-150, indicating that up-regulation of p53 contributed to the suppression to tumor growth. Our study provides a novel strategy for cancer therapy through the development of anti-miRNAs.

Introduction

microRNAs (miRNAs) are small non-coding RNA molecules (19-22 nucleotides) that bind to mRNA in a sequence-specific manner (1). Through complementary binding to mRNA targets, each microRNA has the distinct capability to potentially regulate the expression of hundreds of genes and thereby modulates several cellular pathways including proliferation and apoptosis (2).

Importantly, miRNAs play critical roles in the development and progression of several types of cancers (3,4). Dependent upon the nature of their target gene(s), miRNAs may function as tumor suppressors by down-regulating target oncogenes (e.g. let-7 and miR-15/16) or as oncogenes by negatively controlling genes that regulate tumor cell differentiation and apoptosis (e.g. miR-155 and miR-21) (5). Indeed, several miRNAs are reported to have important roles in different types of cancer, including acute myelogenous leukemia (6,7), chronic myelogenous leukemia (CML) (8-10), lung cancer (11,12), and breast cancer (13), among others. miRNAs have also been shown to play a role in cancer progression through the modulation of cellular adhesion, cell matrix and signaling activities (14,15). In addition, miRNAs have been shown to regulate the expression of hypoxia-related genes and of the vascular endothelial growth factor (16,17).

Emerging evidence shows that deregulation of miRNAs may be a primary driver of cancer initiation and progression. The rules of Watson and Crick base-pairing guide the binding of miRNAs to their target genes. In order to circumvent this interaction, anti-microRNA oligonucleotides (AMOs) have been generated to directly compete with endogenous miRNAs (18). Several modifications of AMOs have been used to improve their effectiveness and stability such as the addition of 2’-O-methyl and 2’-O-methoxyethyl groups to the 5’ end of the molecule (19). AMOs conjugated to antagonists have also been generated and have been described to inhibit microRNA activity in vivo efficiently (20). miR-21, miR-155, and miR-17-5p are proven oncogenic miRNAs overexpressed in several solid cancers (21,22). Lu et al designed three regular AMOs
(AMO-21, AMO-155 and AMO-17) antisense to these miRNAs which produced significant decreases in cancer cell survival (23). AMOs specific to miR-21, and miR-181a have also been shown to inhibit A549 cell growth by inducing apoptosis and S-phase arrest (24). In a previous study, we demonstrated that miR-20, miR-106, and miR-150 acted as oncogenic miRNAs and inhibition of the expression of these miRNAs by AMOs could suppress A549 cell proliferation (25).

The above studies illustrate that using AMOs specific to oncogenic miRNA is a crucial approach to cancer therapy. Therefore, we constructed an AMOs-expression vector and investigated its suppressive role in A549 cell proliferation. We found that miR-150 expression decreased and the apoptotic number of A549 cells increased after AMO-150-expression vector transfection. We also found that tumor volume became smaller and the weight was reduced in the AMO-150-expression vector-treated group compared with the control group. Our results indicated that inhibition of miR-150 expression would be an effective option for lung cancer therapy.

Materials and methods

Vector construction. The polymerase III promoter (H1 promoter) was amplified by PCR from human genomic DNA and the Tc vector (containing the H1 promoter) was constructed as previously described (26). Then, the H1 promoter from the Tc vector was cloned into the pREP4 vector (Invitrogen) to form the PH vector. The antisense RNA targeting miRNA oligonucleotides were annealed and cloned into the PH vector using HindIII and Afl II to designate the PR-ASO-150 vector.

Transient transfection was carried out using Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). A549 cells were transfected with 1 µg plasmid (PR-ASO-150) and inhibition of the expression of these miRNAs by AMOs could suppress A549 cell proliferation (25).

Detection of growth inhibition rate. After cells were transfected with PR-ASO-150 for 72 h, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) assay was carried as follows: 1x10^4 cells were cultured into each well of 96-well flat-bottom microtiter plates and 10 µl MTT (5 mg/ml) were added 4 h before the end of incubation, the supernatant was removed and 100 µl dimethyl sulfoxide (DMSO) were added to determine the OD value at 570 nm using an enzyme-linked immunosorbent assay reader (ELX800). The growth inhibition rate was detected according to the studies of Ren et al. and O'Donovan et al. (27,28). The following formula was used: growth inhibition rate = (OD_control - OD_sample)/OD_control x 100 (%).

Detection of apoptotic cells by flow cytometry. For A549 cells, cells were trypsinized and gently washed with serum-containing medium. The samples (1x10^5 cells) were centrifuged for 5 min at 500 x g and the supernatant was discarded. Cells were resuspended in 500 µl of 1X binding buffer. Propidium iodide (5 µl) was added. The cells were incubated at room temperature for 5 min in the dark followed by analysis by flow cytometry (Beckman-Coulter, Inc., USA). The FL2 channel was chosen for detecting PI staining. The percentage of cells in the apoptotic phase was calculated.

miRNA detection by real-time PCR. miRNAs were isolated by a mirVana™ miRNA kit (Ambion) and poly (A) was added using a poly(A) polymerase (Ambion). The CDNA was synthesized by the RT primer: 5′-AACATGTACAGTCCATGGAGTGATTGTTTGGAAAGCTAGCGGTTTTCTGACTTCGGTGAAAACCC-3′; the reverse primer was 5′-TTAGAGGGGTTCGACGCCGAGTCAGAAAACCGCTAGCTTTCCAAAAACTTCCAACCTTTGTACACAGTGTTGGGG-3′. The forward coding sequence of an antisense RNA was 5′-AGCTCTCCCACTTGTTACAGTCCATGGAGTATTGTTTGGAAAGCTAGCGGTTTTCTGACTTCGGTGAAAACCC-3′. The reverse sequence was 5′-TTAAGAGGGGTTCGACGCCGAGTCAGAAAACCGCTAGCTTTCCAAAAACTTCCAACCTTTGTACACAGTGTTGGGG-3′ (the underlined sequence in primer shows the restriction enzyme cut site).

Cell culture. A549 cells (human lung adenocarcinoma epithelial cells) were obtained from the Shanghai Institute of Cell Biology. A549 cells were maintained in F12 medium (Gibco) supplemented with 10% calf serum (Hyclone), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C with 5% CO₂.

Transient transfection was carried out using Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). The cells (5x10⁵) were transfected with 1 µg plasmid (PR-ASO-150) and 2.5 µl lipofectamine. The medium was changed after 8 h. After transfection with PR-ASO-150 and incubation for 72 h, samples were collected and the morphological changes of A549 cells were observed under an inverted microscope. All transfections were carried out in triplicate.

Detection of growth inhibition rate. After cells were transfected with PR-ASO-150 for 72 h, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) assay was carried as follows: 1x10^4 cells were cultured into each well of 96-well flat-bottom microtiter plates and 10 µl MTT (5 mg/ml) were added 4 h before the end of incubation, the supernatant was removed and 100 µl dimethyl sulfoxide (DMSO) were added to determine the OD value at 570 nm using an enzyme-linked immunosorbent assay reader (ELX800). The growth inhibition rate was detected according to the studies of Ren et al. and O'Donovan et al. (27,28). The following formula was used: growth inhibition rate = (OD_control - OD_sample)/OD_control x 100 (%).

Detection of apoptotic cells by flow cytometry. For A549 cells, cells were trypsinized and gently washed with serum-containing medium. The samples (1x10^5 cells) were centrifuged for 5 min at 500 x g and the supernatant was discarded. Cells were resuspended in 500 µl of 1X binding buffer. Propidium iodide (5 µl) was added. The cells were incubated at room temperature for 5 min in the dark followed by analysis by flow cytometry (Beckman-Coulter, Inc., USA). The FL2 channel was chosen for detecting PI staining. The percentage of cells in the apoptotic phase was calculated.
HFK Bio-Technology) using $5 \times 10^6$ cells in 100 µl F12 medium per injection. Once the mice developed palpable tumors, caliper measurements were taken daily and tumor volume was calculated using the formula: $V = \text{length} \times \text{width}^2/2$ (length $>$ width). When tumors grew to a volume of $\sim 150$ mm$^3$, 5 µg PR-ASO-150 plasmid in 40 µl PBS with the 12.5 µl Lipofectamine (Invitrogen) were delivered intratumorally 3 times in 3-day intervals. Mice were sacrificed 5 days after the last treatment, and tumors were collected and prepared for subsequent analysis. All animal experiments were performed under an approved animal study protocol of the Binzhou Medical University.

**Statistical analysis.** The SAS software was used to analyze the significance of the results. The Student’s t-test was used for intergroup comparison, and a p-value $<0.05$ was considered significant.

**Results**

**Construction of the PR-ASO-150 vector.** To drive the $\sim 20$-bp antisense RNA expression, the 200-bp polymerase III promoter (H1 promoter) was amplified by PCR from human genomic DNA (Fig. 1A). The H1 promoter was cloned into the PREP4 vector from the Tc plasmid to construct the PH vector. The H1 promoter sequence was verified using an automatic DNA sequencer (Biosune, Shanghai, China; data not shown). Then, the coding antisense RNA (specific to miR-150) was cloned downstream of the H1 promoter to form the PR-ASO-150 vector, in which the ‘TTTTT’ sequence was the stop code before the hairpin structure (Fig. 1B).

**Inhibition of miR-150 expression in A549 cells.** After cells were transfected with PR-ASO-150, the miRNAs were isolated and poly (A) was added. qRT-PCRs were performed with the SuperTaq Polymerase following the manufacturer’s instructions. The results showed that miR-150 expression in A549 cells was lower in the PR-ASO-150-treated group than in the control group (Fig. 2).

**Cell growth inhibition rate and apoptosis after PR-ASO-150 treatment.** After PR-ASO-150 treatment, the number of A549 cells found alive was lower than that of the control groups.
Inhibition of cell proliferation by anti-miRNA

In addition, the MTT assay was performed after the cells were exposure to PR-ASO-150 for 72 h. Inhibition of the miR-150 expression by PR-ASO-150 resulted in a higher growth inhibition rate (Fig. 3B), indicating that PR-ASO-150 could inhibit A549 cell proliferation by regulating miR-150 expression. Detection of the apoptotic A549 cells by flow cytometry, demonstrated that the percentage of cells in the apoptotic phase was higher (28.99%) in the PR-ASO-150 group compared to that in the control group (3.38%) (Fig. 3C).

Inhibition of A549 cell growth in nude mice. After A549 cells were injected into the lower back of 6-8-week old BALB/C-nu mice, PR-ASO-150 plasmids were delivered intratumorally to observe the suppressive action of ASO-150 in A549 cells via regulation of miR-150 expression. The tumor volume and weight decreased by PR-ASO-150 treatment (Fig. 4, Table I). In a previous study, we found that p53 was a downstream factor negatively regulated by miR-150 (25). To investigate whether the changes of tumor volume and weight were related to p53 expression, p53 expression in the tumor was assessed by Western blotting. p53 expression increased after PR-ASO-150 treatment (Fig. 5), indicating that up-regulation of p53 is related to the suppression in tumor growth.

Discussion

Since their discovery in nematodes, the role of miRNAs in cancer has been extensively studied. Their frequent location at fragile sites, common break-points or regions of amplification or loss of heterozygosity reveal that miRNAs may play significant roles in human carcinogenesis (29). Anti-microRNA oligonucleotides (AMOs) specific to oncogenic miRNA is a potential approach to cancer therapy. In a previous study, miR-150 was found to act as an oncogene (25). Therefore, in this study, we constructed the PR-ASO-150 vector to express antisense RNA specific to miR-150 and found that it can inhibit miR-150 expression effectively in A549 cells. We also found that tumor volume decreased after PR-ASO-150 treatment compared to control vector treatment. The mechanism may be related to p53 expression, which was higher after PR-ASO-150 treatment compared with control group.

Changes in microRNA expression may be a downstream effect of potent oncogenes or tumor suppressors in the carcinogenesis process, such as the modulation of miR-34 by p53 (30). miR-21 is an oncogene, which plays a key role in programmed cell death resistance in cancer cells. miR-21 has been implicated in practical aspects of oncogenic life: the promotion of cell proliferation, invasion, metastasis, and evasion of apoptosis (31). miR-373 has been shown to regulate cell cycle progression by targeting PPP6C transcripts in vitro. The expression of miR-373 may also promote HCC cell proliferation (32).

In this study, we showed that A549 cell growth was suppressed by PR-ASO-150, which expressed antisense RNA specific to miR-150. The oncogenic role of miR-150 in cancer is also supported by the study of Zhou et al, in which miR-150 levels were observed to be higher in cancer than in normal cells, and increased expression of miR-150 in cancer epithelial cells was reported to decrease P2X7 mRNA by activation of miR-150 instability target sites located at the 3'-UTR-P2X7 (33). miR-150 has been found to be up-regulated in hepatoblastoma (34) in gastric cancer cell lines and tissues (35) and in colorectal cancer specimens with liver metastases (36).
Ectopic expression of miR-150 can promote tumorigenesis and proliferation of gastric cancer cells.

Our studies as well as those of others indicate that miR-150 plays an important role in cancer cell growth progression and cellular metastasis. The discovery of miR-150 acting as an oncogene may open an unprecedented path in the targeted approach to cancer treatment. Antisense oligonucleotides, generally named anti-miRNAs, can bind directly to miRNAs and block their activity. With time, the AMOs in cells may be subjected to degradation by RNase in vivo and the inhibition to cell proliferation would disappear, though several chemical modifications to these oligonucleotides have been carried out to improve their efficacy (37). In order to express antisense RNA for a longer time, a vector-based anti-miRNA can express antisense RNA effectively, even constantly if it was intertagated into genome. Therefore, we designed the anti-miR-150 expression vector (PR-ASO-150) regulated by using the H1 promoter and the ‘TTTTT’ sequence following a hairpin as the stop code. Our results demonstrate that miR-150 expression was effectively suppressed after PR-ASO-150 treatment of A549 cells.

In summary, we constructed an anti-miRNA vector (PR-ASO-150) to inhibit miR-150 expression in A549 cells. Tumor growth was suppressed in nude mice and p53 expression was higher after PR-ASO-150 treatment compared with the control group. Our study provides novel insight into cancer therapy by development of ASOs.

Acknowledgements

This study was supported by the NCET, ‘Taishan scholar’ position and National Natural Science Foundation (no. 30801324), the Shandong Science and Technology Committee (no. 2007BS03048, ZR2009CQ033, ZR2009CL005) and the Foundation of Shandong Educational Committee of China (no. J09LF11). We also thank Xiuxian Wang and Lixia Zhang (Experimental Central Lab of Binzhou Medical University) for their help with the flow cytometry analyses.

References